Indication
Secondary Progressive Multiple Sclerosis (SPMS)
Stage
Open-label, follow-on trial to MAESTRO-01
Location of Study
Canada and Europe
47 trial sites in 10 countries
Clinical Trials
MS TSX: Quote: 0.37 | Change: +0.01 | 03.11.10 | 11:56:00 MST